Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients

Inclusion Criteria:

• Patients with histologically- or cytologically- documented NSCLC who presentunresectable stage IIIA-IIIB-IIIC disease, according to 8th version of theInternational Association for the Study of Lung Cancer Staging Manual in ThoracicOncology).

• ECOG 0-1.

• PDL1>1%.

• Age ≥ 18 years at time of study

• Patients without progression after cCRT, that are going to receive IO treatment (Durvalumab) for 12 months as subsequent treatment as per standard clinical practice

• Patient capable of proper therapeutic compliance and accessible for correctfollow-up.

• Patients must have signed, dated and IRB/EC-approved written informed consent formin accordance with regulatory and institutional guidelines.

Exclusion Criteria:

• Patients who refuse to sign and date an IRB/IEC-approved written informed consentform.

• No possibility of venipuncture

• Any medical, mental, or psychological condition which in the opinion of theinvestigator would not permit the patient to complete the study or understand thepatient information.